We are currently advancing a pipeline of small molecule, oral antagonists of the chemokine receptor CXCR4. We believe that inhibition of the CXCR4 receptor creates the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

We are evaluating the safety and efficacy of our lead candidate, mavorixafor, a first-in-class oral CXCR4 antagonist, in a number of clinical programs: a fully enrolled Phase 3 clinical trial for the treatment of patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease; a Phase 1b clinical trial in combination with standard of care, ibrutinib for the treatment of patients with a rare B-cell lymphoma called Waldenstrom macroglobulinemia; and as monotherapy in a Phase 1b clinical trial for the treatment of patients with Severe Congenital Neutropenia (SCN) and other chronic neutropenia disorders.

We are also advancing several small-molecule pre-clinical candidates with desirable characteristics of next-generation oral CXCR4 antagonists.


X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.